Download PDFPDF

Glucocorticoids in the treatment of early and late RA
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Glucocorticoids in Rh A.

    Dear Editor

    The recent leader was well balanced and comprehensive.[1]

    However, there was no mention of why they are used and by whom. Thus, the mortality data from ARAMIS and other dara-bases showing an increased mortality in rheumatoid patients taking prednisone is acceptable if it's reserved for the more severe patient. The published evidence suggests to me that use is more physician determined than pa...

    Show More
    Conflict of Interest:
    None declared.